Literature DB >> 1797821

Stereoselective determination of R(-)- and S(+)-MK-571, a leukotriene D4 antagonist, in human plasma by chiral high-performance liquid chromatography.

R S Robinett1, J Y Hsieh.   

Abstract

A stereoselective high-performance liquid chromatographic method that utilizes fluorescence detection was developed for the selective and sensitive quantification of R(-)- and S(+)-enantiomers of MK-571 (1), a potent and specific leukotriene D4 antagonist, in human plasma. Racemic 1 was isolated from the acidified plasma using solid-phase extraction and the resulting residue was successfully reacted with isobutyl chloroformate and R(+)-1-(1-naphthyl)ethylamine in triethylamine-acetonitrile medium to form the diastereomer of each enantiomer. A structural analogue of 1 was used as internal standard. The derivatized sample was dissolved in 1,1,2-trichlorotrifluoroethane and an aliquot was chromatographed on a (R)-urea chiral column using a mobile phase containing 89% triethylamine-pentane (3:1000, v/v), 10% 2-propanol, and 1% acetonitrile at a flow-rate of 1.5 ml/min. The fluorescence response (excitation wavelength, 350 nm; emission wavelength, 410 nm) was linear (r2 greater than 0.999) for concentrations of enantiomers of 1 from 0.05 micrograms/ml, the lowest quantitation limit, up to 2.5 micrograms/ml. Intra-day coefficients of variation at 0.05 microgram/ml were 2.4% for the R(-)-isomer and 2.0% for S(+)-isomer. The corresponding inter-day coefficients of variation for R(-)- and S(+)-1 were 2.6 and 3.6%, respectively. The utility of the methodology was established by analysis of plasma samples from male volunteers receiving single intravenous and oral doses of racemic 1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797821     DOI: 10.1016/0378-4347(91)80210-4

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.

Authors:  J I Schwartz; D J Margolskee; T D Bjornsson; V C Williams; J Y Hsieh; C C Lin; J D Rogers
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.

Authors:  M Depré; D J Margolskee; J Y Hsieh; A Van Hecken; A Buntinx; I De Lepeleire; J D Rogers; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Dose-dependent kinetics of the enantiomers of MK-571, and LTD4-receptor antagonist.

Authors:  M Depré; D J Margolskee; A Van Hecken; J S Hsieh; A Buntinx; P J De Schepper; J D Rogers
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.